Pharsight

Brilinta generic

Brilinta is an antiplatelet drug owned by Astrazeneca. This drug contains the active ingredient ticagrelor and is available in oral tablet dosage forms. Brilinta has a total of 6 drug patents, none of which have expired. The drug was first authorized for market use on 20 July, 2011.

When will Brilinta generic be available?

The last patent for Brilinta, US10300065 with the title 'Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction', is set to expire on 27 July, 2036. Therefore, it is expected that the generics of Brilinta will start to become available after this date. This process might be accelerated due to Para IV filing.

Brilinta uses

Brilinta is used for the treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It effectively does so by reducing the rate of cardiovascular death, myocardial infarctions, and strokes. This is accomplished by administering 60 mg of ticagrelor, the active ingredient in Brilinta, twice daily to patients receiving 75-100 mg of aspirin daily and have or had acute coronary syndrome. ticagrelor’s antiplatelet properties prevent blood clots, thereby reducing the risk of these events.

Brilinta patent expiration

Brilinta holds a total of six patents, with the final one, 'Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction' (Patent US10300065*PED), set to expire on 27 July, 2036. Following this, the market awaits the entrance of Brilinta generics. Below is the detail of the patent:

EPO Oppostions filed on Brilinta

Brilinta dosage

Want to ask something?